Understanding Nanoparticle Surfaces: A New Analytical Approach for Nanomedicine Research

Discover how Resolian used iGC-SEA to characterise polymer nanoparticle surface energy for Loughborough University, generating new insights into protein corona formation and nanomedicine development.

ANALYTICAL SCIENCES

CASE STUDY

Background

When nanoparticles enter the bloodstream, they don’t remain bare. Proteins rapidly adsorb onto their surfaces, forming what is known as a protein corona. This corona changes how nanoparticles interact with cells, affects their circulation time, and influences their therapeutic efficacy. For researchers developing polymer-based nanomedicines, understanding and controlling this process is fundamental to designing particles that behave predictably in a biological environment.

The surface energy of a nanoparticle is a key determinant of protein corona formation. Yet for many research groups, the analytical tools to quantify nanoparticle surface energy in a rigorous, reproducible way are simply not available in-house.

The Challenge 

Dr Amanda Pearce and the Pearce Polymer Group at Loughborough University research the surface properties of polymer nanoparticles in biological contexts. Their work focuses on how nanoparticle surface chemistry drives interactions with biomolecules in the body, with direct implications for nanomedicine design and efficacy.

The group faced a specific analytical gap:

  • Protein corona formation is heavily influenced by nanoparticle surface energy, both dispersive and specific components.
  • Quantitative characterisation of surface energy at the nanoparticle level requires specialist instrumentation and expertise not available within the university.
  • Without this data, critical questions about how changes in polymer chemistry, particle size, and surface charge influence surface energy, and therefore biological behaviour, could not be answered.

The team needed a partner with both the capability and the scientific understanding to make this work.

Characterising Polymer Nanoparticle Surface Energy for Nanomedicine Research

Our Approach 
Tailored Support

Resolian’s team designed a two-stage characterisation programme tailored to the research requirements.

In the first stage, scanning electron microscopy (SEM) was used to assess the presence and morphology of nanoparticles within lyophilised samples. This early-stage characterisation was critical: it provided the Pearce Group with direct feedback on their sample preparation and production methods, enabling them to optimise nanoparticle yield and consistency before progressing to surface energy analysis.

Once sufficient nanoparticle production was confirmed, Resolian applied iGC-SEA to quantify dispersive and specific surface energies across a range of polymer nanoparticle variants in addition to human serum albumin (HSA). These values were then used to determine work of cohesion and adhesion to protein (albumin), providing a direct quantitative link between surface energy and the biological interactions driving protein corona formation.

Results

The Solution

Resolian’s iGC-SEA analysis provided the Pearce Group with quantitative surface energy profiles that had not previously been achievable for these materials. The data revealed how changes in polymer chemistry, particle size, and surface charge each influence surface energy, offering a direct quantitative link to the biological interactions driving protein corona formation.

The SEM stage delivered an additional benefit: imaging data informed improvements to the group’s sample preparation methods, strengthening the quality and reproducibility of subsequent analyses. Rather than simply delivering a measurement, Resolian’s involvement shaped the research programme from the outset.

What This Means

This collaboration demonstrates that iGC-SEA has meaningful applications well beyond pharmaceutical powder characterisation. By providing quantitative surface energy data for polymer nanoparticles, Resolian enabled the Pearce Group to address questions that were previously out of reach analytically.

The resulting dataset contributes new assays and reference data to the polymer nanomedicine literature, and supports a broader understanding of how surface energy can be used as a design parameter in next-generation drug delivery systems. For research teams working at the intersection of materials science and medicine, it points to what becomes possible with the right analytical partner.

Polymer nanoparticle surface energy - iGC-SEA at Resolian

Working on a complex characterisation challenge
that requires specialist analytical expertise?

Resolian partners with both industry and academic research teams to deliver precise, decision-ready surface energy data.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.